FI113377B - Yhdistelmäviruspartikkelin valmistusmenetelmä käytettäväksi syöpäsolun kasvainilmiasun estossa - Google Patents

Yhdistelmäviruspartikkelin valmistusmenetelmä käytettäväksi syöpäsolun kasvainilmiasun estossa

Info

Publication number
FI113377B
FI113377B FI911997A FI911997A FI113377B FI 113377 B FI113377 B FI 113377B FI 911997 A FI911997 A FI 911997A FI 911997 A FI911997 A FI 911997A FI 113377 B FI113377 B FI 113377B
Authority
FI
Finland
Prior art keywords
making
viral particle
recombinant viral
inhibiting tumor
cancer cell
Prior art date
Application number
FI911997A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI911997A0 (fi
Inventor
Wen-Hwa Lee
Huei-Jen Su Huang
Eva Y H P Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI113377(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of FI911997A0 publication Critical patent/FI911997A0/fi
Application granted granted Critical
Publication of FI113377B publication Critical patent/FI113377B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
FI911997A 1988-10-31 1991-04-25 Yhdistelmäviruspartikkelin valmistusmenetelmä käytettäväksi syöpäsolun kasvainilmiasun estossa FI113377B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26582988A 1988-10-31 1988-10-31
PCT/US1989/004808 WO1990005180A1 (en) 1988-10-31 1989-10-30 Products and methods for controlling the suppression of the neoplastic phenotype

Publications (2)

Publication Number Publication Date
FI911997A0 FI911997A0 (fi) 1991-04-25
FI113377B true FI113377B (fi) 2004-04-15

Family

ID=23012037

Family Applications (1)

Application Number Title Priority Date Filing Date
FI911997A FI113377B (fi) 1988-10-31 1991-04-25 Yhdistelmäviruspartikkelin valmistusmenetelmä käytettäväksi syöpäsolun kasvainilmiasun estossa

Country Status (9)

Country Link
EP (2) EP0792931A3 (ja)
JP (1) JPH03505675A (ja)
AT (1) ATE161039T1 (ja)
AU (3) AU638954B2 (ja)
CA (1) CA2001815C (ja)
DE (1) DE68928491T2 (ja)
FI (1) FI113377B (ja)
NO (1) NO314222B1 (ja)
WO (1) WO1990005180A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US7105156B1 (en) 1987-09-17 2006-09-12 The Regents Of The University Of California Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
KR970005049B1 (ko) * 1990-07-16 1997-04-11 더 리젠츠 오브 더 유니벌시티 오브 캘리포니아 바쿨로비루스 발현 시스템, 이 벡터 시스템을 포함하는 이종성 무척추동물 숙주세포, 상기 시스템에 의해 생산되는 가용성의 정제된 야생형 망막아세포종 폴리펩티드 및 이 폴리펩티드의 생산 방법
US5569824A (en) * 1991-01-04 1996-10-29 Baylor College Of Medicine Transgenic mice containing a disrupted p53 gene
ES2158847T3 (es) * 1991-01-16 2001-09-16 Univ Johns Hopkins Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre.
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5330892A (en) * 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
JPH10509879A (ja) * 1994-11-28 1998-09-29 ジェネティック セラピー， インコーポレイテッド 複製欠陥ベクターを用いる、組織特異的処置、診断方法、および組成物
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
HUP0004240A2 (en) * 1997-10-25 2001-03-28 Roche Diagnostics Gmbh Suspension packing cell lines for retrovirus vestors
FR2843526A1 (fr) * 2002-08-16 2004-02-20 Inst Nat Sante Rech Med Utilisation d'animaux heterozygotes cdx2+/-pour tester des factures cancerogenes ou anti-cancereux
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4942123A (en) * 1987-09-17 1990-07-17 The Regents Of The University Of California ppRB110 -phosphoprotein the retinoblastoma susceptibility gene product

Also Published As

Publication number Publication date
NO314222B1 (no) 2003-02-17
EP0440744A1 (en) 1991-08-14
DE68928491D1 (de) 1998-01-22
EP0440744B1 (en) 1997-12-10
DE68928491T2 (de) 1998-06-04
WO1990005180A1 (en) 1990-05-17
NO911690D0 (no) 1991-04-29
EP0792931A3 (en) 1999-05-19
AU4635089A (en) 1990-05-28
CA2001815A1 (en) 1990-04-30
AU638954B2 (en) 1993-07-15
AU4915593A (en) 1994-01-13
CA2001815C (en) 2002-09-03
EP0440744A4 (en) 1992-07-01
ATE161039T1 (de) 1997-12-15
EP0792931A2 (en) 1997-09-03
AU670624B2 (en) 1996-07-25
AU7042196A (en) 1997-02-20
FI911997A0 (fi) 1991-04-25
NO911690L (no) 1991-06-25
JPH03505675A (ja) 1991-12-12

Similar Documents

Publication Publication Date Title
FI113377B (fi) Yhdistelmäviruspartikkelin valmistusmenetelmä käytettäväksi syöpäsolun kasvainilmiasun estossa
MX9705039A (es) Genes y proteinas de muerte celular programada.
DE69535407D1 (de) Verfahren zur induzierung von genexpression mittels ionisierender strahlung
SE8900247L (sv) Ett nytt bifunktionellt tillvaextmodulerande glykoprotein
ATE103333T1 (de) Hohe proteinsyntheserate in hefe.
EP0280474A3 (en) Macromolecular platinum antitumor compounds
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ATE391175T1 (de) Multidrug resistenz gen
DE69435218D1 (de) Regulation der Genexpression von bcl-2
DE69031830D1 (de) Hemmung der transformation der zellen mit erhöhter purin-metabolischer enzymaktivität
DE69021742D1 (de) Verfahren zum Nachweis von kleinzelligem Carzinom und die Verwendung von Sequenzen, die Acylpeptid-Hydrolase codieren, für diesen zweck.
DE68927104T2 (de) Gentherapie unter verwendung von genschmelzen für genetische und erworbene störungen
ATE283921T1 (de) Zell- und/oder tumor-spezifische promotor- abhängige änderung der gezielten expression des herpes gamma 34.5 gens
ATE175237T1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung.
DK0520029T3 (da) Fremgangsmåde og forbindelse til behandling af maligne forekomster, hvortil der er knyttet en proteinkinase
ATE329055T1 (de) Methode zur erstellung von genexpressionsprofilen
IL126257A (en) Immuno-magnetic cell separation for use in identification of genes associated with site-preferenced cancer methastasis formation
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
ATE264387T1 (de) Verfahren zur auslösung von apoptose in zellen